MediciNova Of Japan To Seek COPD Approval For Asthma Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's MediciNova announced it would seek approval for its MN-221 drug for the additional indication of treating chronic obstructive pulmonary diseases. The company began developing the drug for treating acute asthma attacks, but getting the other indication would give the company its first drug for treating COPD. Such treatments are expected to be in high demand because the ailment is caused by smoking. (Click here for more - a subscription may be required